NCT01228903

Uric Acid and the Endothelium in CKD

Is Uric Acid a Mediator of Endothelial Dysfunction in Patients With Chronic Kidney Disease?

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will test the hypothesis that uric acid impairs the function of vessels in patients with kidney disease

Detailed description

The purpose of the study is to understand the effect of lowering serum uric acid levels on vascular function in individuals with chronic kidney disease by comparing the effects of: 1\) Allopurinol therapy and 2) Placebo. Patients will receive: 3 month study drug (either allopurinol or placebo), with assessment of serum uric acid levels and vascular function.

Conditions

• Kidney Disease

Interventions

Type	Name	Description
DRUG	Allopurinol	Xanthine oxidase inhibitor- effective at lowering uric acid levels.
OTHER	Placebo	Placebo tablets with no active ingredient

Timeline

• Start date: 2010-10-01
• Primary completion: 2016-09-01
• Completion: 2016-09-01
• First posted: 2010-10-27
• Last updated: 2017-06-28
• Results posted: 2017-02-23

Locations

1 site across 1 country: United States